HVRRY vs. AZN
HVRRY (Hannover Re) and AZN (AstraZeneca PLC) are both stocks. HVRRY operates in Insurance - Reinsurance (Financial Services), while AZN operates in Drug Manufacturers - General (Healthcare). Over the past 10 years, HVRRY returned 12.58%/yr vs 15.97%/yr for AZN. At a 0.29 correlation, their price movements are largely independent.
Performance
HVRRY vs. AZN - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, HVRRY achieves a -12.88% return, which is significantly lower than AZN's 1.85% return. Over the past 10 years, HVRRY has underperformed AZN with an annualized return of 12.58%, while AZN has yielded a comparatively higher 15.97% annualized return.
HVRRY
- 1D
- -0.32%
- 1M
- -9.40%
- YTD
- -12.88%
- 6M
- -7.55%
- 1Y
- -16.13%
- 3Y*
- 12.41%
- 5Y*
- 12.50%
- 10Y*
- 12.58%
AZN
- 1D
- 1.04%
- 1M
- 0.32%
- YTD
- 1.85%
- 6M
- 4.25%
- 1Y
- 29.14%
- 3Y*
- 9.91%
- 5Y*
- 11.83%
- 10Y*
- 15.97%
HVRRY vs. AZN - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
HVRRY Hannover Re | -12.88% | 29.30% | 7.59% | 24.53% | 11.05% | 20.35% | -16.15% | 48.63% | 10.97% | 21.66% |
AZN AstraZeneca PLC | 1.85% | 43.30% | -0.62% | 1.44% | 19.14% | 19.66% | 3.12% | 35.68% | 13.86% | 33.10% |
Correlation
The correlation between HVRRY and AZN is 0.22, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.22 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.22 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.24 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.19 |
Correlation (All Time) Calculated using the full available price history since Jul 13, 2007 | 0.29 |
Fundamentals
HVRRY:
$31.24B
AZN:
$286.33B
HVRRY:
$4.06
AZN:
$6.66
HVRRY:
10.63
AZN:
27.56
HVRRY:
0.32
AZN:
0.04
HVRRY:
1.20
AZN:
4.74
HVRRY:
2.25
AZN:
6.05
HVRRY:
$25.44B
AZN:
$60.44B
HVRRY:
$23.95B
AZN:
$49.37B
HVRRY:
$9.81B
AZN:
$20.47B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
HVRRY vs. AZN — Risk / Return Rank
HVRRY
AZN
HVRRY vs. AZN - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Hannover Re (HVRRY) and AstraZeneca PLC (AZN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| HVRRY | AZN | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.89 | ||
| Sortino ratioReturn per unit of downside risk | -2.87 | ||
| Omega ratioGain probability vs. loss probability | 0.89 | 1.22 | -0.32 |
| Calmar ratioReturn relative to maximum drawdown | -0.91 | 1.91 | -2.81 |
| Martin ratioReturn relative to average drawdown | -1.87 | 5.05 | -6.92 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| HVRRY | AZN | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.74 | 1.15 | -1.89 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.50 | 0.50 | 0.00 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.48 | 0.64 | -0.16 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.39 | 0.50 | -0.11 |
Drawdowns
HVRRY vs. AZN - Drawdown Comparison
The maximum HVRRY drawdown since its inception was -62.80%, which is greater than AZN's maximum drawdown of -48.94%. Use the drawdown chart below to compare losses from any high point for HVRRY and AZN.
Loading charts...
Drawdown Indicators
| HVRRY | AZN | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -62.80% | -48.94% | -13.86% |
Max Drawdown (1Y)Largest decline over 1 year | -17.62% | -15.43% | -2.19% |
Max Drawdown (3Y)Largest decline over 3 years | -17.62% | -27.87% | +10.25% |
Max Drawdown (5Y)Largest decline over 5 years | -31.66% | -27.87% | -3.79% |
Max Drawdown (10Y)Largest decline over 10 years | -44.24% | -27.87% | -16.37% |
Current DrawdownCurrent decline from peak | -17.62% | -12.00% | -5.62% |
Average DrawdownAverage peak-to-trough decline | -8.46% | -11.37% | +2.91% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.56% | 5.80% | +2.76% |
Volatility
HVRRY vs. AZN - Volatility Comparison
The current volatility for Hannover Re (HVRRY) is 5.23%, while AstraZeneca PLC (AZN) has a volatility of 7.49%. This indicates that HVRRY experiences smaller price fluctuations and is considered to be less risky than AZN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| HVRRY | AZN | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 5.23% | 7.49% | -2.26% |
Volatility (6M)Calculated over the trailing 6-month period | 16.58% | 17.47% | -0.89% |
Volatility (1Y)Calculated over the trailing 1-year period | 21.72% | 25.51% | -3.79% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 25.13% | 24.00% | +1.13% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 26.28% | 24.91% | +1.37% |
Dividends
HVRRY vs. AZN - Dividend Comparison
HVRRY's dividend yield for the trailing twelve months is around 5.64%, more than AZN's 2.90% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
AZN AstraZeneca PLC | 2.90% | 1.70% | 2.27% | 2.15% | 2.12% | 2.35% | 2.80% | 2.81% | 3.69% | 3.95% | 5.01% | 4.06% |
HVRRY Hannover Re | 5.64% | 3.19% | 3.10% | 2.75% | 3.15% | 2.92% | 2.75% | 2.19% | 3.27% | 4.55% | 8.64% | 1.19% |
Financials
HVRRY vs. AZN - Financials Comparison
This section allows you to compare key financial metrics between Hannover Re and AstraZeneca PLC. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
HVRRY vs. AZN - Profitability Comparison
HVRRY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Hannover Re reported a gross profit of 7.31B and revenue of 7.31B. Therefore, the gross margin over that period was 100.0%.
AZN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported a gross profit of 12.61B and revenue of 15.29B. Therefore, the gross margin over that period was 82.5%.
HVRRY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Hannover Re reported an operating income of 965.32M and revenue of 7.31B, resulting in an operating margin of 13.2%.
AZN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported an operating income of 4.25B and revenue of 15.29B, resulting in an operating margin of 27.8%.
HVRRY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Hannover Re reported a net income of 722.29M and revenue of 7.31B, resulting in a net margin of 9.9%.
AZN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported a net income of 3.08B and revenue of 15.29B, resulting in a net margin of 20.2%.
Frequently Asked Questions
HVRRY and AZN have a correlation of 0.22, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
AZN has higher volatility (7.49%) compared to HVRRY (5.23%). In terms of maximum drawdown, HVRRY dropped -62.80% vs AZN's -48.94%.
AZN currently has the higher Sharpe Ratio (1.15 vs -0.74), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for HVRRY and AZN
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer